Hasbro (Hasbro Stock Quote, Chart, News, Analysts, Financials NASDAQ:HAS) continues to execute, according to Roth analyst Eric Handler, who reiterated his “Buy” rating and raised his 12-month price target to $120.00 from $105.00 in a Feb. 11 report.
Handler said he remains positive on the name, citing ongoing strength at Wizards of the Coast and a return to growth in Consumer Products. The new target is based on 13.5-times 2026E Adjusted EBITDA and 21-times 2026E EPS.
“Magic still steering the ship; Consumer Products returning to growth,” Handler said, adding that rising free cash flow is supporting deleveraging and a new share repurchase authorization.
Fourth-quarter results came in well ahead of expectations. Net revenue rose 31% year-over-year, compared to Handler’s 17% forecast, driven by 86% growth at Wizards of the Coast, including 141% growth from Magic: The Gathering. Consumer Products grew 7%, marking its first positive quarter since Q2/22. Operating margin expanded 1,180 basis points to 21.8%, above Handler’s 17.2% estimate.
On the back of the momentum, Handler raised his 2026 revenue and adjusted operating income forecasts to $4.897-billion and $1.198-billion, respectively, from $4.714-billion and $1.142-billion. He now expects EPS of $5.70, up from $5.50, though growth will be tempered by higher interest expense and lower other income, creating an estimated $40-million headwind, or about $0.20 per share.
For 2026, Handler expects Wizards of the Coast revenue to increase 6%, supported by an expanded release slate and continued player base growth, while Consumer Products revenue is projected to rise 2.5% with operating leverage driving a 59% increase in adjusted operating income.
Handler forecasts Hasbro will generate $1,421.3-million in Adjusted EBITDA on revenue of $4,896.5-million in fiscal 2026, improving to $1,489.0-million in Adjusted EBITDA on revenue of $5,236.8-million in fiscal 2027.
-30-
Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$ 5.50 target on NervGen Pharma (NervGen Pharma Stock Quote, Chart,… [Read More]
In an April 8 note, Paradigm Capital analyst Scott McAuley maintained his “Speculative Buy” rating on Perimeter Medical Imaging AI… [Read More]
Beacon Securities analyst Doug Cooper said preliminary first-quarter results from Kits Eyecare (Kits Eyecare Stock Quote, Chart, News, Analysts, Financials… [Read More]
Ventum Capital Markets analyst Amr Ezzat moved Blackline Safety (Blackline Safety Stock Quote, Chart, News, Analysts, Financials TSX:BLN) to “Tender”… [Read More]
Research Capital analyst Greg McLeish maintained his “Speculative Buy” rating and $3.00 target on The FUTR Corporation (The FUTR Corporation… [Read More]
In an appearance on BNN Bloomberg Market Call on April 2, RN Croft Financial Group portfolio manager Richard Orrell highlighted… [Read More]